Loading …

Categories

In Conversation

The Journey To Commercialization for a Novel Medical Device Startup: Q&A with Sonavex CEO, David Narrow

The Journey To Commercialization for a Novel Medical Device Startup: Q&A with Sonavex CEO, David Narrow

The Journey To Commercialization for a Novel Medical Device Startup: Q&A with Sonavex CEO, David Narrow May 7, 2019 In the past year Sonavex has landed not one, but two FDA 510(k) clearances for their ultrasound-based medical devices. This first

Q&A with Virginia (Ginny) Espina, PhD, MT(ASCP)

Q&A with Virginia (Ginny) Espina, PhD, MT(ASCP)

Q&A with Virginia (Ginny) Espina, PhD, MT(ASCP) Dr. Ginny Espina is a Research Associate Professor at George Mason University’s Center for Applied Proteomics and Molecular Medicine. She will be the Workshop Director for the upcoming Bio-TracⓇ Symposium, “Laser Microdissection: From

BioHealth Capital Projects

People on the Move

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors GERMANTOWN, Md., July 18, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq:

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held,